The challenges of lung cancer surgery in 2023 (notice n° 178043)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02480cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040818.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Prieto, Mathilde |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | The challenges of lung cancer surgery in 2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 34 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The surgical management of patients with non-small cell lung cancer will remain central to the therapeutic armamentarium in 2023. Around 30 percent of lung cancer patients will undergo surgery. The advent of targeted therapies and immunotherapy has revolutionized the management of patients with advanced lung cancer. Surgery must also continue to innovate and apply the concepts of predictive, personalized, participatory, and preventive medicine (MP4), enabling us to define, by 2023, precision surgery. The objectives are manifold: to reduce post-operative complications and thus have a direct impact on post-operative morbidity and mortality; and to improve overall survival, recurrence-free survival, and patients’ quality of life. This is made possible as much by the availability of new technical tools with the arrival of minimally invasive and robotic surgery, as by the improvement of patient care pathways with, in particular, the development of enhanced recovery after surgery (ERAS) programs. A better understanding of the mechanisms involved in tumor progression, as well as tumor–host interactions, is also essential, making it possible to identify new prognostic factors. Moreover, beyond the tumor stage, various studies have demonstrated that undernutrition, sarcopenia, and the patient’s inflammatory state have a direct impact on post-operative outcomes. A broader vision, centered around the patient, seems to be the key to the innovation of lung cancer surgery in 2023. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | multimodal treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | surgery |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | personalized treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | innovation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lung cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | minimally invasive |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | multimodal treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | surgery |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | personalized treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | innovation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lung cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | minimally invasive |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Daffre, Elisa |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Alifano, Marco |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 9 | 3 | 2023-05-01 | p. 161-166 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-et-therapeutiques-en-oncologie-2023-3-page-161?lang=en">https://shs.cairn.info/journal-innovations-et-therapeutiques-en-oncologie-2023-3-page-161?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux